TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17914134
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat milk (daily dose about 800 mg calcium)
Study: 2194055
Drug: Rokitamycin (RKM)
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin (RKM) dry syrup
Study: 15770505
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia (TIVA)
Study: 23735179
Drug: Vilanterol (VI)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilanterol (VI) 25 μg
Study: 10608202
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diltiazem (0.25 +/- 0.01 mg x kg(‐1)) and nicardipine (5.9 +/- 0.9 microg x kg(‐1) x min(‐1))
Study: 20729233
Drug: 3-monthly 3-week
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-monthly 3-week treatments with oral ciprofloxacin and inhaled colistin
Study: 26643240
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin, 4100 U, 1/12 h for 11 d
Study: 21042116
Drug: Avotermin 200
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avotermin 200 ng/100 μl/linear centimeter, administered once or twice
Study: 21042116
Drug: Avotermin 50
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avotermin 50 ng/100 μl/linear centimeter, administered twice
Study: 19214375
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day alendronate (Group A)
Study: 2453683
Drug: Enoxacin 200
Normalized name: enoxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 200 mg, administered orally the night before the operation, 2 to 4 hours preoperatively, and every 12 hours postoperatively for 36 hours.
Study: 30097463
Drug: SC411 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC411 at 36 mg DHA/kg per day
Study: 10683715
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium salt 50 mg in tablet (Cataflam)
Study: 25580725
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rifapentine and isoniazid
Study: 22681407
Drug: Extended-release hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release hydromorphone
Study: 7574132
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (2 mg/kg)
Study: 16126809
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (800 mg/day for 4 weeks)
Study: 21613452
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 8 g/L of a specific prebiotic mixture (short‐chain galacto‐oligosaccharides and long‐chain fructo‐oligosaccharides, ratio 9:1)
Study: 8741209
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 1 mg/kg or 4 mg/kg
Study: 31278907
Drug: HFNC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC group (O2 [30-60 L/minute] via HFNC)
Study: 31227530
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin for 24 hours followed by oxytocin infusion alone
Study: 27388828
Drug: Paclitaxel-based drug-eluting
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-based drug-eluting balloon (DEB) angioplasty (n = 35)
Study: 31012215
Drug: Rectal barostat
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal barostat study (follow-up after 8-12 years)
Study: 12200355
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 12 mg/kg/d orally from the day preceding conditioning until day 90 after transplantation
Study: 2524362
Drug: Norethisterone enanthate
Normalized name: norethindrone enanthate
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone enanthate 50 mg and estradiol valerate 5 mg (NET-EN/E2-V)
Study: 10764171
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Intranasal and Intravenous PCA)
Study: 1599072
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of pethidine added to 9 ml of 0.25% bupivacaine
Study: 23126645
Drug: Combined simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined simvastatin 40 mg and ezetimibe 10 mg daily
Study: 7939440
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection therapy with papaverine/phentolamine (n = 172 evaluable)
Study: 28077732
Drug: High-Protein breakfast
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Protein breakfast (19-20 g protein)
Study: 28077732
Drug: High-Fiber breakfast
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Fiber breakfast (10-11 g fiber)
Study: 17666915
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/day
Study: 18257182
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 50 mg Clomiphene
Study: 25382328
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose atorvastatin 80 mg/d (HD group)
Study: 12417278
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C administration
Study: 18594319
Drug: TG4010 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4010 monotherapy until disease progression, followed by TG4010 plus the same chemotherapy as in Arm 1
Study: 31480423
Drug: Raw garlic
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw garlic consumption (twice or more per week)
Study: 8775777
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen vaginal cream
Study: 23063288
Drug: Dementia patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dementia patients prescribed warfarin
Study: 23290819
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus cisplatin (175 mg/m(2) + 60 mg/m(2))
Study: 24593836
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) treatment
Study: 31769337
Drug: Twice-daily functional
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily functional electrostimulation group (TFEG; n = 17)
Study: 7453623
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine A/USSR/90/77
Study: 12500513
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue 0.5 mg.kg‐1.h‐1
Study: 9692655
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice/day
Study: 8356542
Drug: Rectal hydrophilic
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal hydrophilic gel of methohexital (25 mg/kg)
Study: 11502785
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration
Study: 24428466
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg weekly
Study: 28806957
Drug: Artemisinin-based combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-based combination therapy (ACT)
Study: 18976472
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine
Study: 7041728
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of vasopressin (40 U/h)
Study: 28549161
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment Control (STC)
Study: 15343351
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose
Study: 25990055
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium 1 mg/d for 8 weeks
Study: 7554521
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CyA) 5 mg/kg/day and prednisolone 10 mg/day for up to 8 months
Study: 3139705
Drug: Protein-polysaccharide vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-polysaccharide vaccine (23 volunteers)
Study: 24164102
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid treatment
Study: 11742886
Drug: Whole-grain meal
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain meal daily for 16 weeks
Study: 16546738
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline at daily dose of 4 to 6 mg/kg for 16 weeks
Study: 24287976
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel applied to surgical site in 6 patients.
Study: 17240929
Drug: Whitening paint-on
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whitening paint-on gel with polyethylene strip barrier
Study: 7617798
Drug: Intravenous yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous yohimbine (0.4 mg/kg)
Study: 14708414
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (2 mg/kg)
Study: 16229114
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (CC) 16 mg + Hydrochlorothiazide (HCT) 12.5 mg
Study: 7913205
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion
Study: 11973171
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin (Control group)
Study: 9537454
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with thymosin alpha1 (TA1) and interferon (IFN)
Study: 1053432
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray containing phosphate-buffered saline (PBS) with human serum albumin
Study: 18214709
Drug: Low-dose IV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IV cyclophosphamide (LD-CYC)
Study: 29332237
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of acetaminophen
Study: 23111035
Drug: Video game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video game play (more than 10 hours weekly)
Study: 19730966
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of granisetron 0.1 mg iv and promethazine 6.25 mg iv
Study: 12548201
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone acetate/5 microg ethinyl estradiol
Study: 6094655
Drug: Conventional antiulcer
Normalized name: ANTIULCER AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiulcer agents (Control)
Study: 31492797
Drug: GRACE risk
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GRACE risk score and associated treatment recommendations
Study: 22500948
Drug: Extended-release niacin/laropiprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin/laropiprant (ERN/LRPT)
Study: 15470966
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (morning light, evening light, placebo)
Study: 19572082
Drug: Withholding anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding anticoagulant therapy after negative CCUS
Study: 17631801
Drug: Low-dose Dinggui
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Dinggui Oil (DGO-L, 0.8 g, 3 times daily)
Study: 23177514
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily for the first 3 weeks of each 4 week cycle
Study: 21729277
Drug: Complex oral
Normalized name: vitamin B complex Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex oral health care (OHC) intervention
Study: 31455425
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous (IV) zoledronic acid (ZA) in postmenopausal women.
Study: 30109375
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group informed about the real nature of the cream
Study: 21167363
Drug: Monthly training
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly training for 4 months
Study: 10706042
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 800 mg four times daily for 120 days (ACV)
Study: 27655325
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 4 mL/Kg of crystalloid over 5 minutes
Study: 22398668
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cilostazol
Study: 1287138
Drug: Ceftibuten 400
Normalized name: ceftibuten 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 400 mg once daily
Study: 8031347
Drug: Porcine surfactant
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine surfactant (4 g in 50 ml) delivered via bronchoscope
Study: 28448426
Drug: Filorexant 10
Normalized name: Filorexant
DrugBank: Filorexant (DB12158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filorexant 10 mg nightly
Study: 7552517
Drug: Three 100
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 100 microgram doses of the inactivated HIV‐1 antigen in incomplete Freund's adjuvant (IFA)
Study: 16846587
Drug: Weekly betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly betamethasone
Study: 25376448
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg BIW for 12 weeks followed by 50 mg QW for 12 weeks
Study: 15548814
Drug: Niacin 500
Normalized name: niacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 500 mg
Study: 19952712
Drug: Continued protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued protease inhibitor regimen
Study: 15672051
Drug: Intragastric balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric balloon treatment
Study: 8917026
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ranitidine at 6.25 mg/hr (n = 9)
Study: 12051570
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 80 mg/day Ginkgo special extract EGb 761
Study: 322817
Drug: Oral flucloxacillin
Normalized name: cloxacillin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flucloxacillin (250 mg six-hourly for four days)
Study: 23856779
Drug: Deleobuvir 100
Normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deleobuvir 100 mg q8h for 5 days
Study: 23856779
Drug: Deleobuvir 200
Normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deleobuvir 200 mg q8h for 5 days
Study: 23710718
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure therapy (NPT)
Study: 19702597
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg/day (n=9)
Study: 15902161
Drug: Sham ExMI
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ExMI treatment
Study: 17560293
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus L-arginine (3 g/day) in subjects with high ADMA
Study: 17560293
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus L-arginine (3 g/day) in subjects with low ADMA
Study: 11555383
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) at approximately half the microgram dose for 6 months
Study: 27606973
Drug: Etanercept monotherapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept monotherapy
Study: 7503614
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lisinopril)
Study: 27803392
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy (IAT)
Study: 26621909
Drug: Persistently elevated
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistently elevated C-reactive protein (CRP) level (≥ 5 mg/L at both baseline and 24 weeks after ART initiation)
Study: 24445737
Drug: UVA irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA irradiation of the skin with two standard erythemal doses
Study: 26945817
Drug: Antioxidant-pregabalin combination
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant-pregabalin combination
Study: 15309258
Drug: Dexpanthenol nasal
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol nasal ointment (5%)
Study: 2204333
Drug: Continuous interpleural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interpleural infusion of bupivacaine (n = 8)
Study: 14769785
Drug: Sulfafurazole (sulphisoxazole)
Normalized name: sulfafurazole
DrugBank: Sulfisoxazole (DB00263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfafurazole (sulphisoxazole) 50 mg/kg body weight, given once a day for six months
Study: 7746775
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 500 micrograms (two puffs of Becloforte) with a 750 ml spacer
Study: 31339676
Drug: Low-dose efavirenz
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose efavirenz (EFV400)
Study: 30766533
Drug: IL-1β blocker
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1β blocker anakinra
Study: 12942722
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CA) monotherapy - 300 mg/day
Study: 12942722
Drug: Maximal androgenic
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal androgenic block (MAB) - CA + surgical castration - 200 mg/day
Study: 23943299
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (HT)
Study: 27883215
Drug: Adalimumab combination
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab combination therapy
Study: 17907591
Drug: CFC-based budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CFC-based budesonide inhaler therapy